US FDA Taps Szarama as Acting Head of Vaccine Unit
May 1 (Reuters) – The U.S. Food and Drug Administration has named Katherine Szarama as the acting director of its vaccines and biologics unit, a Health and Human Services official told Reuters on Friday, replacing Vinay Prasad, whose turbulent tenure came to an end this week. The appointment comes days after FDA Commissioner Marty Makary said no decision had been reached on Prasad’s permanent successor and that he expected an announcement “in the coming weeks.” Szarama will lead the Center for Biologics Evaluation and Research (CBER), which regulates vaccines, gene therapies and the blood supply. Prasad left the agency after a term marked by controversy, including several high-profile decisions on rare disease drugs and vaccines. The news was first reported by Politico. Before joining the agency, Prasad, an oncologist, was known for his vocal criticism of U.S. drug and vaccine policies, especially concerning COVID-19 mandates. His time at CBER was marked by repeated clashes, most notably the FDA’s rejection of a Huntington’s disease gene therapy from Dutch drug developer UniQure. The U.S. drug regulator called …






